NanoVelcro Chip for CTC enumeration in prostate cancer patients
| Autor: | Zheng Luo, Min Song, Xiaochun Xu, William W.-L. OuYang, Jiaoti Huang, Matthew Rettig, Edwin M. Posadas, Chen Shao, Leland W.K. Chung, Mitch A. Garcia, Dongxia Wu, Wei-Han OuYang, Shuang Hou, Xuan Xuan, Jake Lichterman, Yi-Tsung Lu, Libo Zhao, Hsian-Rong Tseng, Qinglin Shen |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Treatment response medicine.medical_specialty Cell Count Article General Biochemistry Genetics and Molecular Biology Prostate cancer Circulating tumor cell Internal medicine Enumeration Humans Medicine Silicon nanowires Molecular Biology Aged Aged 80 and over business.industry Disease progression Prostatic Neoplasms Microfluidic Analytical Techniques Middle Aged Neoplastic Cells Circulating Prognosis medicine.disease Chip Immunohistochemistry Immunology Valid Biomarker business |
| Zdroj: | Methods. 64:144-152 |
| ISSN: | 1046-2023 |
| DOI: | 10.1016/j.ymeth.2013.06.019 |
| Popis: | Circulating tumor cells (CTCs) are one of the most crucial topics in rare cell biology and have become the focus of a significant and emerging area of cancer research. While CTC enumeration is a valid biomarker in prostate cancer, the current FDA-approved CTC technology is unable to detect CTCs in a large portion of late stage prostate cancer patients. Here we introduce the NanoVelcro CTC Chip, a device composed of a patterned silicon nanowire substrate (SiNW) and an overlaid polydimethylsiloxane (PDMS) chaotic mixer. Validated by two institutions participating in the study, the NanoVelcro Chip assay exhibits very consistent efficiency in CTC-capture from patient samples. The utilized protocol can be easily replicated at different facilities. We demonstrate the clinical utility of the NanoVelcro Chip by performing serial enumerations of CTCs in prostate cancer patients after undergoing systemic therapy. Changes in CTC numbers after 4–10 weeks of therapy were compared with their clinical responses. We observed a statistically significant reduction in CTCs counts in the clinical responders. We performed long-term follow up with serial CTC collection and enumeration in one patient observing variations in counts correlating with treatment response. This study demonstrates the consistency of the NanoVelcro Chip assay over time for CTC enumeration and also shows that continuous monitoring of CTC numbers can be employed to follow responses to different treatments and monitor disease progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect